References
  1. Dodge JA, Morison S, Lewis PA, Coles EC, Geddes D, Russell G et al. Incidence, population, and survival of cystic fibrosis in the UK, 1968-95. UK Cystic Fibrosis Survey Management Committee. Arch Dis Child 1997;77:493-6.
  2. Mandal A, Kabra SK, Lodha R. Cystic Fibrosis in India: Past, Present and Future. J Pulm Med Respir Res 2015,1: 002.
  3. Kabra SK, Kabra M, Ghosh M, Verma IC. Cystic fibrosis–an Indian perspective on recent advances in diagnosis and management. Indian J Pediatr 1996;63:189-98.
  4. Kabra SK, Kabra M, Lodha R, Shastri S, Ghosh M, Pandey RM et al. Clinical profile and frequency of delta f508 mutation in Indian children with cystic fibrosis. Indian Pediatr 2003;40:612-9.
  5. Kabra SK, Kabra M, Ghosh M, Khanna A, Pandey RM. Cystic fibrosis in Indian children: clinical profile of 62 children. PediatrPulmonol 1999;19: 337.
  6. Singh M, Prasad R, Kumar L. Cystic fibrosis in North Indian children. Indian J Pediatr 2002;69: 627-629.
  7. Shwachman H, Kulezycky LL. Long term study of 105 patients with cystic fibrosis. Am J Dis Child1958; 96: 6-9.
  8. Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter H et al. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry. European Respir J 2014; 43:125-133.
  9. Kerem E, Reisman J, Corey M, Canny G, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 32:1187–1191.
  10. Huang NN, Schidlow DV, Szatrowski TH, Palmer J, Laraya-Cuasay LR, Yeung W et al. Clinical features, survival rate and prognostic factors in young adults with cystic fibrosis. Am J Med 1987;82:871–879.
  11. Courtney JM, Bradley J, Mccaughan J, O’connor TM, Shortt C, Bredin CP et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007; 42:525–532.
  12. Scotet, V., L’Hostis, C., & Férec, C. The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery. Genes. 2020;11:589.
  13. Rajendra P. Molecular and Functional Basis of Cystic Fibrosis in Indian Patients: Genetic, Diagnostic and Therapeutic Implications. Ann Natl Acad Med Sci ( India),  2018;54:216-230.
  14. Prasad R, Sharma H, Kaur G. Molecular Basis of Cystic Fibrosis Disease: An Indian Perspective. Indian J Clinical Biochem 2010; 25:335–341.
  15. Cystic Fibrosis Foundation Patient Registry, Annual Data Report 2007. Cystic Fibrosis Foundation, Bethesda, USA 2008.
  16. Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B. Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997; 145:794–803.
  17. O’Connor GT, Quinton HB, Kahn R, Robichaud P, Maddock J, Lever T et al. Case-mix adjustment for evaluation of mortality in cystic fibrosis. Pediatr Pulmonol 2002;33:99-105.
  18. Johansen HK, Nir M, Hoiby N, Koch C, Schwartz M. Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation. Lancet 1991;337:631–634.
  19. Bell SC, Saunders MJ, Elborn JS, Shale DJ. Resting energy expenditure and oxygen cost of respiration in patients with cystic fibrosis. Thorax 1996; 51:126–131.
  20. Fried MD, Durie PR, Tsui LC, Corey M, Levison H, Pencharz PB. The cystic fibrosis gene and resting energy expenditure. J Pediatr 1991;119:913–916.
  21. Frangolias DD, Mahenthiralingam E, Rae S, Raboud JM, Davidson AG, Wittmann R et al. Burkholderia cepacian infection in cystic fibrosis: Variable disease course. Am J Resp Crit Care Med 1999;160:1572–1577.
  22. McCloskey M, McCaughan J, Redmond AO, Elborn JS. Clinical outcome after the acquisition of Burkholderia cepacia in patients with cystic fibrosis. Ir J Med Sci 2001;170:28–31.
  23. Tablan OC, Chorba TL, Schidlow DV, White JW, Hardy KA, Gilligan PH et al. Pseudomonas cepacia colonisation in patients with cystic fibrosis: Risk factors and clinical outcome. J Pediatr 1985;107:382–387.
  24. LiPuma JJ, Dasen SE, Nielson DW, Stern RC, Stull TL. Person to- person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet 1990;336:1094-1096.